Carbamylation of immunoglobulin abrogates activation of the classical complement pathway. 2014

Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.

Post-translational modifications of proteins significantly affect their structure and function. The carbamylation of positively charged lysine residues to form neutral homoitrulline occurs primarily under inflammatory conditions through myeloperoxidase-dependent cyanate (CNO-) formation. We analyzed the pattern of human IgG1 carbamylation under inflammatory conditions and the effects that this modification has on the ability of antibodies to trigger complement activation via the classical pathway. We found that the lysine residues of IgG1 are rapidly modified after brief exposure to CNO- . Interestingly, modifications were not random, but instead limited to only few lysines within the hinge area and the N-terminal fragment of the CH2 domain. A complement activation assay combined with mass spectrometry analysis revealed a highly significant inverse correlation between carbamylation of several key lysine residues within the hinge region and N-terminus of the CH2 domain and the proper binding of C1q to human IgG1 followed by subsequent complement activation. This severely hindered complement-dependent cytotoxicity of therapeutic IgG1 . The reaction can apparently occur in vivo, as we found carbamylated antibodies in synovial fluid from rheumatoid arthritis patients. Taken together, our data suggest that carbamylation has a profound impact on the complement-activating ability of IgG1 and reveals a pivotal role for previously uncharacterized lysine residues in this process.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008239 Lysine An essential amino acid. It is often added to animal feed. Enisyl,L-Lysine,Lysine Acetate,Lysine Hydrochloride,Acetate, Lysine,L Lysine
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D002956 Citrulline
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D003485 Cyanates Organic salts of cyanic acid containing the -OCN radical. Cyanate

Related Publications

Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
June 1994, Biochimica et biophysica acta,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
April 1979, The Journal of clinical investigation,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
March 1989, Infection and immunity,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
December 1993, Behring Institute Mitteilungen,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
April 2005, Nihon rinsho. Japanese journal of clinical medicine,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
March 2004, Xenotransplantation,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
February 1994, The Journal of allergy and clinical immunology,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
January 1976, Kidney international,
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
April 1986, Journal of immunology (Baltimore, Md. : 1950),
Catalin Koro, and Ewa Bielecka, and Anders Dahl-Knudsen, and Jan J Enghild, and Carsten Scavenius, and Johan G Brun, and Veronika Binder, and Annelie Hellvard, and Brith Bergum, and Roland Jonsson, and Jan Potempa, and Anna M Blom, and Piotr Mydel
January 1985, Advances in immunology,
Copied contents to your clipboard!